Evidence question

PubMed sourcedAbstract-based analysisUpdated Sep 2026Human reviewedUpdated Aug 2026

Evidence / Menopause & Women's Health

CoverageMenopause & Women's Health

Does hormone replacement therapy increase breast cancer risk?

Reviewed by Neal Rouzier, MD, Preventive Medicine · Aug 2026

Updated Aug 2026·10 studies analyzed·3 core studies·1 conflicting·Applies to: perimenopausal and early postmenopausal women

Bottom line

Combined estrogen-progestin therapy is associated with a small increased breast cancer risk in WHI and observational data. Estrogen-alone in hysterectomized women showed lower risk in WHI, but interpretation depends on regimen, duration, and individual risk factors.[1–6]

Evidence confidence

Evidence Confidence

High
LimitedModerateHigh

Multiple high-quality studies directly address this question, with generally consistent findings.

Key uncertainty. Bioidentical compounded regimens lack equivalent long-term trial data.

Ask RAGMD

Get the live evidence synthesis

10 complimentary queries. Full clinical intelligence — PubMed citations, conflict analysis, Evidence Confidence — with 7-day free trial.

Ask this questionStart free trialWhy physicians use RAGMD

Also asked

What percentage does HRT increase breast cancer risk?▼

WHI combined estrogen-progestin therapy showed roughly eight extra breast cancers per 10,000 women per year in the trial population. Absolute excess depends on regimen, duration, and baseline risk.

Which HRT has the lowest risk of cancer?▼

Estrogen-alone therapy in hysterectomized women showed lower breast cancer incidence in WHI than combined estrogen-progestin. Transdermal routes may carry lower VTE risk than oral regimens in observational data.

WHI estrogen progestin breast cancer▼

The WHI estrogen-plus-progestin arm demonstrated increased invasive breast cancer with combined therapy. Interpretation requires attention to age, time since menopause, and individual risk factors.

HRT breast cancer▼

HRT breast cancer risk is regimen-dependent: combined therapy carries a small excess in trial data, while estrogen-alone patterns differ. Bioidentical compounded combinations lack equivalent long-term cancer trials.

Estrogen therapy cancer risk women▼

Combined estrogen-progestin therapy is associated with a small increased breast cancer risk in WHI and observational data. Estrogen-alone in hysterectomized women showed lower risk in WHI, but interpretation depends on regimen, duration, and individual risk factors.

Body of evidence

Clinical Evidence Brief

RAGMD analyzed 7 relevant studies.

Overall finding

5 studies address breast cancer, with weighted findings showing mixed findings. 4 studies address mortality, with weighted findings showing mixed findings. 3 studies address venous thromboembolism, with weighted findings showing harm. 2 studies address fractures, with weighted findings showing harm. 3 randomized or systematic-review reports and 4 observational studies address treatment.

Evidence by outcome

Direction: ↑ Favors treatment / reassuring · ↓ Harm signal · ↔ No clear effect · ± Mixed · ↗ Observational link · ? Unclear

Mixed

Breast cancer

moderate · 5 studies

5 studies address breast cancer, with weighted findings showing mixed findings. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 12117397PMID 32721007PMID 41307293PMID 23543779PMID 12927427
Mixed

Mortality

moderate · 4 studies

4 studies address mortality, with weighted findings showing mixed findings. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 12117397PMID 32721007PMID 41307293PMID 23543779
Harm signal

Venous thromboembolism

high · 3 studies

3 studies address venous thromboembolism, with weighted findings showing harm. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 12117397PMID 41307293PMID 42027787
Harm signal

Fractures

high · 2 studies

2 studies address fractures, with weighted findings showing harm. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 12117397PMID 41307293
Unclear

Long-term cognitive decline / dementia

moderate · 1 study

1 study addresses long-term cognitive decline / dementia, with weighted findings showing unclear findings. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 41307293
Unclear

Vasomotor symptom associations

moderate · 1 study

1 study addresses vasomotor symptom associations, with weighted findings showing unclear findings. This is a patient-reported / subjective outcome.

Patient-reported

Studies

PMID 41307293

Magnitude / clinical importance

Validated effect estimates in the analyzed set include RR 1.17; HR = 1.55; relative risk 1.66. Statistical significance is not the same as clinical importance.

Interpret magnitude in absolute terms for the patient in front of you, not from relative estimates alone.

Agreement across studies

Most studies agree on vasomotor symptom associations (unclear findings), while breast cancer findings are mixed findings and less consistent across domains.

Supports main conclusion: 3 · Neutral / mixed: 3 · Credible conflicting: 1

Study counts describe the landscape; RAGMD weights studies according to design, quality, and directness.

Conflicting findings

  • Current use of hormone-replacement therapy (HRT) increases the incidence of breast cancer.
  • Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women.
  • The influence of menopausal hormone therapy on breast cancer remains unsettled with discordant findings from observational studies and randomized clinical trials.
  • Long-term follow-up of women using hormone therapy suggests that the risk profiles vary between combined hormone therapy and oestrogen-only therapy.

Risks & harms

5 studies report safety-relevant findings. Design mix: Randomized controlled trial, Study design not clearly classified, Narrative review. Rare-event inference should not rest on underpowered trials alone.

Who this applies to

Most studies included perimenopausal and early postmenopausal women.

What remains uncertain

  • Bioidentical compounded regimens lack equivalent long-term trial data.
  • Bioidentical compounded regimens lack equivalent long-term trial data.

Clinical takeaway

Counsel on regimen-specific breast cancer risk: combined estrogen-progestin differs from estrogen alone in hysterectomized women. Use the lowest effective dose for the shortest duration that meets symptom and indication goals, with annual reassessment of personal risk factors.

Mixed

Breast cancer?

Mixed findings

moderate[12117397 · 32721007 · 41307293 · 23543779 · 12927427]

Mixed

Mortality?

Mixed findings

moderate[12117397 · 32721007 · 41307293 · 23543779]

Harm signal

Venous thromboembolism?

Harm

high[12117397 · 41307293 · 42027787]

Harm signal

Fractures?

Harm

high[12117397 · 41307293]

Unclear

Long-term cognitive decline / dementia?

Unclear findings

moderate[41307293]

Unclear

Vasomotor symptom associations?

Unclear findings

moderate[41307293]

Unclear

Fertility / spermatogenesis?

Unclear findings

moderate[41307293]

Reassuring

Hormone therapy effects on cognition?

Benefit

limited[35017407]

3 randomized or systematic-review reports and 4 observational studies address treatment. Weighted treatment findings show mixed findings.

3 RCT / systematic review · 4 observational

Large randomized trials strongly influence the conclusion

3 landmark studies with randomized or systematic-review designs strongly inform this conclusion.

Supporting studies provide additional context

6 supporting studies add context beyond the core evidence base.

Regimen & duration

Observational and supporting studies provide context and do not outrank higher-appropriateness designs.

Long-term uncertainty

1 study with different findings reduces complete certainty.

9 analyzed studies

Strongest evidence

JAMA2020

Landmark studyPMID 32721007

Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials.

The influence of menopausal hormone therapy on breast cancer remains unsettled with discordant findings from observational studies and randomized clinical trials. To assess the association of prior randomized use of estrogen plus progestin or prior randomized use of estrogen alon

RCT
Evidence
Relevance

Important conflicting evidence

Lancet (London, England)2003

Conflicting evidencePMID 12927427

Breast cancer and hormone-replacement therapy in the Million Women Study.

Current use of hormone-replacement therapy (HRT) increases the incidence of breast cancer. The Million Women Study was set up to investigate the effects of specific types of HRT on incident and fatal breast cancer.

Study
Evidence
Relevance

Supporting literature

Long-term hormone therapy for perimenopausal and postmenopausal women.

Practice guideline for the treatment and management of iatrogenic premature ovarian insufficiency.

Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study.

+3 more

More in this focus area

Related evidence analyses

Other structured clinical questions in Menopause & Women's Health.

Does hormone replacement therapy reduce cardiovascular risk in early menopause?

The timing hypothesis suggests earlier initiation may differ from late initiation, where WHI showed harm for combined therapy. Current guidelines emphasize individualized risk assessment rather than routine cardioprotection.

14 linked studies

Does hormone replacement therapy increase venous thromboembolism risk?

Oral estrogen increases venous thromboembolism risk compared with no therapy. Transdermal estrogen appears to carry lower thrombotic risk in observational studies and is often preferred in women at elevated VTE risk.

14 linked studies

Is there a critical timing window for cardiovascular benefit from HRT?

The critical-window concept proposes that starting HRT closer to menopause may yield different cardiovascular effects than starting later. WHI subgroup analyses inform but do not prove this hypothesis for routine practice.

14 linked studies

Is progestogen required to protect the endometrium with estrogen therapy?

Systemic estrogen in women with a uterus requires adequate progestogen exposure to prevent endometrial hyperplasia. Micronized progesterone and progestins differ in metabolic and VTE profiles.

14 linked studies

Go deeper on Menopause & Women's Health

Full evidence synthesis, study comparisons, conflicting evidence, and expert commentary are available with RAGMD. Ask follow-up questions, explore related topics, and see how the evidence has evolved.

Ask RAGMDExplore Menopause & Women's HealthView pricing